help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kappy, M.
Right arrow Articles by Clemons, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kappy, M.
Right arrow Articles by Clemons, R.

Journal of Clinical Endocrinology & Metabolism, Vol 69, 1087-1089, Copyright © 1989 by Endocrine Society

ARTICLES

Suppression of gonadotropin secretion by a long-acting gonadotropin- releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty

M Kappy, T Stuart, A Perelman and R Clemons
Children's Health Center of St. Joseph's Hospital, Phoenix, Arizona 85013.

The GnRH analog leuprolide acetate has been shown to be effective in the treatment of precocious puberty when given as a daily sc injection. We studied the effectiveness of a single im dose of a new depot form of leuprolide in suppressing estradiol and gonadotropin secretion in children with precocity. Five girls with previously untreated precocity showed significant decreases in basal serum estradiol and FSH levels and in peak LH levels (after GnRH testing) 30 days after a single im dose of leuprolide acetate for depot suspension. Mean peak FSH levels also fell greatly, but the difference was not significant. No adverse effects were noted during the first 4-6 months of monthly im injections. Depot im leuprolide appears to be effective in suppressing estradiol and gonadotropin secretion, and may be a useful method of treating children with central precocious puberty.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
J.-C. Carel, N. Lahlou, O. Jaramillo, V. Montauban, C. Teinturier, M. Colle, C. Lucas, and J. L. Chaussain
Treatment of Central Precocious Puberty by Subcutaneous Injections of Leuprorelin 3-Month Depot (11.25 mg)
J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4111 - 4116.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society